Biodistribution and displacement studies of the selective 5-ht2areceptor antagonist i-5-i-r91150 in the normal dog

Nuclear Medicine Communications

Volumn 23, Issue 10, 2002, Pages 1019-1027

  Peremans, K ^a   Audenaert, K ^a   Jacobs, F ^b   Dumont, F ^b   DE VOS, F ^b   Van de wiele, C ^b   Vandecapelle, M ^b   Van bree, H ^a   Verschooten, F ^a   Slegers, G ^a   Mertens, J ^a   Dierckx, R ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Biodistribution; Canine brain; Displacement study; I 5 I R91150; Serotonin 2A receptor

Indexed keywords

5 IODO R91150 I 123; IODINE 123; KETANSERIN; R 91150; RADIOLIGAND; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG; PIPERIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD; BRAIN; BRAIN CORTEX; CEREBELLUM; CONTROLLED STUDY; COST; DISSOCIATION; DOG; DOSE TIME EFFECT RELATION; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG UPTAKE; EYE; GALLBLADDER; HEART; LIVER; LUNG; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; RECEPTOR AFFINITY; WHOLE BODY SCINTISCANNING; ANIMAL; BINDING COMPETITION; DRUG EFFECT; METABOLISM; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYNTHESIS; TISSUE DISTRIBUTION; WHOLE BODY COUNTING;

ANIMALS; BINDING, COMPETITIVE; BRAIN; DOGS; KETANSERIN; PIPERIDINES; RADIOPHARMACEUTICALS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; WHOLE-BODY COUNTING;

EID: 0036793488     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200210000-00013     Document Type: Article

References (56)

1. Busatto GF. Radioligands for brain 5-HT2A receptor imaging in vivo: why do we need them? Eur J Nucl Med 1996; 23: 867-870.
2. Nobler MS, Mann JJ, Sackeim HA. Serotonin, cerebral blood flow and cerebral metabolic rate in the geriatric major depression and normal aging. Brain Res Reviews 1999; 30: 250-263.
3. 2A receptor binding index in deliberate self harm patients. Eur J Nucl Med 2001; 28: 175-182.
4. 18F] altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction. Brain Res 1998; 813: 167-171.
5. Olivier B, Mos J. Rodent models of aggressive behavior and serotonergic drugs. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16: 847-870.
6. Olivier B, Mos J, Van Oorschot R, Hen R. Serotonin receptors and animal models of aggressive behavior. Pharmacopsychiatry 1995; 28: 80-90.
7. Westergaard GC, Suomi SJ, Higley DE, Mehlman PT. CSF 5-HIAA and aggression in female macaque monkeys: species and interindividual differences. Psychopharmacology (Berlin) 1999; 146: 440-446.
8. Doudet D, Hommer D, Higley JD, et al. Cerebral glucose metabolism, CSF 5-Hiaa levels and aggressive behavior in rhesus monkeys. Am J Psychiatry 1995; 152: 1782-1787.
9. Higley JD, Mehlman PT, Higley SB, et al. Excessive mortality in young free-ranging male nonhuman primates with low cerebrospinal fluid 5-hydroxyindoleacetic acid concentrations. Arch Gen Psychiatry 1996; 53: 537-543.
10. Higley JD, Linnoila M. Low central nervous system serotonergic activity is traitlike and correlates with impulsive behavior: a nonhuman primate model investigating genetic and environmental influences on neurotransmission. Ann NY Acad Sci 1997; 836: 39-57.
11. Mehlman PT, Higley JD, Faucher I, et al. Low CSF 5-HIAA concentrations and severe aggression and impaired impulse control in non-human primates. Am J Psychiatry 1994; 151: 1485-1491.
12. Winberg S, Myrberg AA, Nilsson GE. Agonistic interactions affect brain serotonergic activity in an acanthopterygiian fish: the bicolor damselfish (Pomacentrus partitus). Brain Behav Evol 1996; 48: 213-220.
13. Popova NK, Voitenko NN, Kulikov AV, Avgustinovich DF. Evidence for the involvement of central serotonin in mechanism of domestication of silver foxes. Pharmacol Biochem Behav 1991; 40: 751-756.
14. Delville Y, Melloni RH, Ferris CF. Behavioral and neurobiological consequences of social subjugation during puberty in golden hamsters. J Neurosci 1998; 18: 2667-2672.
15. Reisner IR, Mann JJ, Stanley M, Huang Y, Houpt KA. Comparison of cerebrospinal fluid monoamine metabolite levels in dominant-aggressive and non-aggressive dogs. Brain Res 1996; 714: 57-64.
16. Reisner IR. Assessment, management, and prognosis of canine dominance-related aggression. Vet Clin North Am Small Anim Pract 1997; 27: 479-495.
17. Asberg M, Traskman L, Thoren P. 5-HIAA in the cerebrospinal fluid. A biochemical suicide predictor? Arch Gen Psychiatry 1976; 33: 1193-1197.
18. Arango V, Underwood MD, Gubbi AV, Mann JJ. Localized alterations in pre- and postsynaptic serotonin binding sites in the ventrolateral prefontal cortex of suicide victims. Brain Res 1995; 688: 121-133.
19. 18F] deuteroaltanserin. Psychiatry Res 2001; 106: 81-93.
20. Baron JC, Samson Y, Comar D, et al. Etude in vivo des récepteurs sérotoninergiques centraux chez l'homme par tomographie à émission de positions. Rev Neurol 1985; 141: 537-545.
21. Wong DF, Wagner HN, Dannals RF, et al. Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science 1984; 226: 1393-1396.
22. Frost JJ, Dannals RF, Mayberg HS, et al. Regional localization of serotonin-2 receptors in man using C-11-N-methylketanserin (NMKET) and PET. J Nucl Med 1987; 28: 600-604.
23. 11C-methyl)-2-Br-LSD. Synapse 1987; 1: 393-398.
24. 18F)-fluoroethyl analog of altanserin, a serotonin S2 receptor ligand. J Label Compd Radiopharm 1991; 30: 374-375.
25. 18F]-fluoroethylketanserin and PET. Neurosci Lett 1991; 123: 23-26.
26. 18F-setorperone during depressive illness and antidepressant treatment with clomipramine. Biol Psychiatry 1999; 45: 180-186.
27. 18F-altanserin: results in young normal controls. J Cereb Blood Flow Metab 1995; 15: 787-797.
28. Terriere D, Janssen P, Gommeren W, et al. Evaluation of radioiodo-4-amino-N-(1-(4-fluorophenoxy)-propyl)-4-methyl-4-piperidinyl)-5-iodo-2-methoxybenzamide as a potential 5HT2A receptor tracer for SPE(C)T. Nucl Med Biol 1995; 22: 1005-1010.
29. Mertens J, Terriere D, Sipido V, et al. Radiosynthesis of a new radioiodinated ligand for serotonin-5HT2A-receptors, a promising tracer for gamma-emission tomography. J Label Compd Radiopharm 1995; 34: 795-801.
30. 123I-5-I-R91150, a selective 5-HT2A ligand for single photon emission tomography in healthy subjects. Eur J Nucl Med 1997; 24: 119-124.
31. 123I)R93274 as a SPECT radiotracer for imaging 5-HT2A receptors. Eur J Pharmacol 1997; 321: 285-293.
32. 123I-5-I-R91150, a new single photon emission tomography ligand for 5-HT2A receptors: influence of age and gender in healthy subjects. Eur J Nucl Med 1998; 25: 1617-1622.
33. Travis M, Busatto G, Pilowsky L, et al. 5-HT2A receptor blockade in patients with schizophrenia treated with risperidone and clozapine. A SPET study using the novel 5-HT2A ligand 123I-5-I-R-91150. Br J Psychiatry 1998; 173: 236-241.
34. Van Laere K, Audenaert K, Dumont F, et al. Frontal 5-HT2A binding potential is decreased in anorexia nervosa patients. J Nucl Med 2000; 41: 201P.
35. Maes F, Vandermeulen D, Suetens P. Automated multimodal image registration by maximization of mutual information: from theory, implementation and validation to a useful tool in routine clinical practice. IEEE Trans Med Imaging 1997; 16: 187-198.
36. Pazos A, Probst A, Palacios J. Serotonin receptors in the human brain-IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience 1987; 21: 123-139.
37. Pazos A, Cortes R, Palacios JM. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res 1985; 346: 231-249.
38. Lopez-Gimenez JF, Vilaro MT, Palacios J, Mengod G. Mapping of 5-HT2A receptors and their mRNA in monkey brain: (3H)MDL100.907 autoradiography and in situ hybridization studies. J Comp Neurol 2001; 429: 571-589.
39. Hamada S, Senzaki K, Hamaguchi-Hamada K, et al. Localization of 5-HT2A receptor in rat cerebral cortex and olfactory system revealed by immunohistochemistry using two antibodies raised in rabbit and chicken. Mol Brain Res 1998; 54: 199-211.
40. Wepierre J, Cohen Y, Rapin J. Accumulation of ephedrine, norephedrine, amphetamine and tyramine labeled with carbon 14 in pigmented and non-pigmented eyes of rats. Arch Int Pharmacodyn Ther 1975; 217: 342-350.
41. Debing I, Ijzermen A, Vauquelin G. Melanosome binding and oxidation-reduction properties of synthetic L-DOPA-melanin as in vitro tests for drug toxicity. Mol Pharmacol 1988; 33: 470-476.
42. Aula P, Kaila T, Huupponen R, Salminen L, Lisalo E. Prostaglandin F2 alpha binding to bovine ocular and synthetic melanin in vitro. Pharmacol Toxicol 1989; 65: 100-103.
43. Steiner K, Buhring KU, Merck E. The melanin binding of bisopropol and its toxicological reference. Lens Eye Toxic Res 1990; 7: 319-333.
44. Koike T, Kitazuma H, Mukai H. Tissue distribution of NS-49, a phenethylamine alpha 1A adrenoreceptor agonist. Arzneimittelforschung 2001; 51: 402-407.
45. Leysen JE, Janssen P, Heylen L, et al. Receptor interactions of new antipsychotics: relation to pharmacodynamic and clinical effects. Int J Psychiatry Clin Pract 1998; 2: S3-S17.
46. Anderson A, Ruehl W, Fleischman L, Stenstrom K, Entriken T, Cummings B. DNA damage and apoptosis in the aged canine brain: relationship to Abeta deposition in the absence of neuritic pathology. Prog Neuro-Psychopharmacol Biol Psychiatry 2000; 24: 787-799.
47. Torp R, Head E, Cotman C. Ultrastructural analyses of beta-amyloid in the aged dog brain: neuronal beta-amyloid is localized to the plasma membrane. Prog Neuropsychopharmacol Biol Psychiatry 2000; 24: 801-810.
48. Head E, Thornton P, Tong L, Cotman C. Initiation and propagation of molecular cascades in human brain aging: insight from the canine model to promote successful aging. Prog Neuropsychopharmacol Biol Psychiatry 2000; 24: 777-786.
49. Brown GL, Linnoila M. CSF serotonin metabolite (5-HIAA) studies in depression, impulsivity, and violence. J Clin Psychiatry 1990; 51(4, Suppl.): 31-41.
50. Virkkunen M, Rawlings R, Tokola R, et al. CSF biochemistries, glucose metabolism, and diurnal activity rhythms in alcoholic, violent offenders, fire setters, and healthy volunteers. Arch Gen Psychiatry 1994; 51: 20-27.
51. Coccaro E, Kavoussi R, Trestman R, Gabriel M, Cooper T, Siever LJ. Serotonin function in human subjects: intercorrelations among central 5-HT indices and aggressiveness. Psychiatry Res 1997; 73: 1-14.
52. Constantino JN, Morris JA, Murphy DL. CSF 5-HIAA and family history of antisocial personality disorder in newborns. Am J Psychiatry 1997; 154: 1773.
53. Kiatipattanasakul W, Nakamura S, Hossain M, et al. Apoptosis in the aged dog brain. Acta Neuropathol 1996; 92: 242-248.
54. Adams B, Chan A, Callahan H, Milgram N. The canine as a model of human cognitive aging: recent developments. Prog Neuro-Psychopharmacol & Biol Psychiat 2000; 24: 675-692.
55. Biegon A, Essar N, Israeli M, et al. Serotonin 5HT2A receptor binding on blood platelets as a state dependent marker in major affective disorder. Psychopharmacology (Berlin) 1990; 102: 73-75.
56. Stockmeier CA. Neurobiology of serotonin in depression and suicide. In: Mann JJ, Stoff DM, eds. The psychobiology of suicide. New York: The New York Academy of Sciences, 1997; 836: 220-232.